October 4, 2010
A customized combination of photodynamic therapy and intravitreal ranibizumab treatment for choroidal neovascularization due to age-related macular degeneration achieved good visual results with a decreased need for re-treatment, a study found.
"Combined customized PDT and ranibizumab treatment can achieve visual results similar to those obtained with intravitreal monotherapy with the advantage of fewer intravitreous injections and reduced potential for adverse effects," the study said.
In the nonrandomized, prospective, interventional study, 53 eyes of 53 patients with subfoveal and juxtafoveal choroidal neovascularization secondary to AMD were treated with PDT and intravitreal Lucentis (ranibizumab, Genentech).
At the end of the 12-month follow-up period, subjects' mean visual acuity had improved by 7.2 letters, and 78.8% maintained or improved their initial vision.
"The central retinal thickness and choroidal neovascularization size decreased to 118 µm and 0.26 disc areas, respectively, from baseline to 12 months," the study authors said.
Sixty-five PDT treatments (mean of 1.22 per patient) were performed, and 126 doses of ranibizumab were injected (mean of 2.37 per patient).
In 21 cases, only a single initial dose of PDT and ranibizumab was required.
Showing posts with label Ranibizumab. Show all posts
Showing posts with label Ranibizumab. Show all posts
Monday, October 4, 2010
Thursday, May 27, 2010
Radiation and Lucentis Combined to Treat Macular Degeneration
by Randall V. Wong M.D
External beam radiation and Lucentis may be combined to treat wet macular degeneration. The results showed the treatment may be very safe and, when combined with anti-VEGF injections such as Lucentis, may decrease the need for frequently repeated injections.
Neovascularization, the growth of abnormal blood vessels, underneath the macular defines “wet macular degeneration.”
Radiation Kills Cells
Radiation treatments have been used in and around the eye to treat tumors. Radiation, in this case, halts the replication of cells. In the case of tumors, the lesions can no longer grow. So too, with neovascularization, new growth is inhibited. This is not the first study that has investigated the use of radiation for wet macular degeneration, but this is one of first trials combining external beam radiation with Lucentis.
Side Effects of Radiation to the Eye
Radiation can be toxic to the eye. It can cause cataracts, damage to the optic nerve and retina. It may also damage the lacrimal (produces tears to the eye) system and cause dry eye.
The investigators were able to dose and administer the radiation safely, seemingly able to avoid the usual complications of external beam radiation.
Treatment Required Fewer Injections of Lucentis
The gold standard for treating wet macular degeneration is now injections with either Lucentis or Avastin. The injections, however, need to be repeated as often as monthly. While highly successful, the need for repeated treatment requires a lot of trips to the office and can be expensive.
The study combined the use of the popular anti-VEGF agent, Lucentis (ranibizumab). The design of the trial required 2 initial injections during the first month of treatment.
52% of patients did not require additional injections for the 12 month study period (they only had 2!).
Also noteworthy, most patients stabilized and actually improved their vision.
What Does This Mean? This is not an approved treatment. It is in no way a true “study,” but this small trial still has some merits. It provides us with a small amount of evidence that alternative treatments using radiation may be useful.
First, recall that anti-VEGF injections, such as Lucentis or Avastin, now standard therapy for wet macular degeneration, were developed for chemotherapy against several types of cancers. The discovery that this improved patients with macular degeneration was coincidental.
For instance, patients receiving chemotherapy for colon cancer started noting improvement in their vision. Evidently, these patients had both cancer and wet macular degeneration.
External beam radiation has long been used for many types of cancer treatments.
In both cases, agents that halt rapidly dividing (i.e. growing) tissues should be effective in both the cancer treatment and the eye disease. The radiation stymies cell replication and the Lucentis (anti-VEGF) inhibits grow of new blood vessels. In the case of cancer, a tumor can not enlarge without blood supply.
So, it makes sense that this may work.
Lastly, this really underscores the need for treatments that do not need to be repeated so frequently, such is the case with Lucentis and Avastin. Right now, most doctors inject as frequently as every 4-6 weeks! Drug delivery systems designed to release drug over an extended period may aid this as well.
External beam radiation and Lucentis may be combined to treat wet macular degeneration. The results showed the treatment may be very safe and, when combined with anti-VEGF injections such as Lucentis, may decrease the need for frequently repeated injections.
Neovascularization, the growth of abnormal blood vessels, underneath the macular defines “wet macular degeneration.”
Radiation Kills Cells
Radiation treatments have been used in and around the eye to treat tumors. Radiation, in this case, halts the replication of cells. In the case of tumors, the lesions can no longer grow. So too, with neovascularization, new growth is inhibited. This is not the first study that has investigated the use of radiation for wet macular degeneration, but this is one of first trials combining external beam radiation with Lucentis.
Side Effects of Radiation to the Eye
Radiation can be toxic to the eye. It can cause cataracts, damage to the optic nerve and retina. It may also damage the lacrimal (produces tears to the eye) system and cause dry eye.
The investigators were able to dose and administer the radiation safely, seemingly able to avoid the usual complications of external beam radiation.
Treatment Required Fewer Injections of Lucentis
The gold standard for treating wet macular degeneration is now injections with either Lucentis or Avastin. The injections, however, need to be repeated as often as monthly. While highly successful, the need for repeated treatment requires a lot of trips to the office and can be expensive.
The study combined the use of the popular anti-VEGF agent, Lucentis (ranibizumab). The design of the trial required 2 initial injections during the first month of treatment.
52% of patients did not require additional injections for the 12 month study period (they only had 2!).
Also noteworthy, most patients stabilized and actually improved their vision.
What Does This Mean? This is not an approved treatment. It is in no way a true “study,” but this small trial still has some merits. It provides us with a small amount of evidence that alternative treatments using radiation may be useful.
First, recall that anti-VEGF injections, such as Lucentis or Avastin, now standard therapy for wet macular degeneration, were developed for chemotherapy against several types of cancers. The discovery that this improved patients with macular degeneration was coincidental.
For instance, patients receiving chemotherapy for colon cancer started noting improvement in their vision. Evidently, these patients had both cancer and wet macular degeneration.
External beam radiation has long been used for many types of cancer treatments.
In both cases, agents that halt rapidly dividing (i.e. growing) tissues should be effective in both the cancer treatment and the eye disease. The radiation stymies cell replication and the Lucentis (anti-VEGF) inhibits grow of new blood vessels. In the case of cancer, a tumor can not enlarge without blood supply.
So, it makes sense that this may work.
Lastly, this really underscores the need for treatments that do not need to be repeated so frequently, such is the case with Lucentis and Avastin. Right now, most doctors inject as frequently as every 4-6 weeks! Drug delivery systems designed to release drug over an extended period may aid this as well.
Subscribe to:
Posts (Atom)
